Sherwin-Williams Company (NYSE:SHW), a paint manufacturer and retailer, reports Q3 earnings that beat the analyst mark while Q4 earnings guidance was in line and fiscal 2014 earnings guidance range beat. Sherwin-Williams Company (NYSE:SHW) reports Q3 earnings of $3.36 per share on revenue of $3.15 billion versus the Street view of $3.22 per share on $3.2 billion, according to Capital IQ estimates. For Q4 2014, the company expects an earnings range of $1.30 to $1.40, versus the Street view of $1.39. For fiscal 2014, the company expects an earnings range of $8.70 to $8.80, versus the Street view of $8.69 per share. SHW trades in a 52-week range of $170.63 to $229.62.Medidata Solutions Inc (NASDAQ:MDSO) posted mixed financial results for Q3, or the quarter ended Sept. 30, 2014, with earnings that matched analysts' expectations, and revenue that fell short; it also provided revenue guidance for fiscal 2014 below forecasts. Medidata Solutions Inc (NASDAQ:MDSO), the provider of cloud-based solutions for clinical research said Q3 GAAP net income was $0.2 million, or $0.00 per diluted share, compared with the prior-year period's $5.3 million, or $0.10 per diluted share. Adjusted non-GAAP net income was $11.1 million, or $0.20 per diluted share, versus $10.7 million, or $0.20 per diluted share in the same quarter the previous year. The Capital IQ analyst estimate is for $0.20 EPS.Revenue was $86 million, up 21% from $70.9 million in the same quarter last year. Analysts were expecting revenue of $87.72 million. The company expects fiscal 2014 revenue to be near the mid-point of $335 million and $340 million, versus the Street view of $342.03 million. Adjusted non-GAAP net income is expected to be between $38 million and $39.5 million. Shares are trading with a 52-week range of $32.10 - $68.21.Pfizer Inc. (NYSE:PFE) reported Q3 results that topped the analyst consensus on Capital IQ, posting adjusted earnings of $0.57 per share on revenue of $12.36 billion, vs. the Street view of $0.55 per share in earnings on revenue of $12.24 billion. For 2014, Pfizer Inc. (NYSE:PFE)expects revenue of $48.7 to $49.7 billion, narrowing its previous view of $48.7 to $50.7 billion. EPS is seen at $2.23 to $2.27 per share, also narrowing the prior view of $2.20 to $2.30 per share. The Street is at $49.4 billion in revenue and earnings of $2.24 per share.United Therapeutics Corporation (NASDAQ:UTHR) turned to a net loss in Q3 ended September 30 after general and administrative, sales and marketing, and research and development expenses increased during the period. But revenues came in stronger, which reflects the continued increase in the number of patients being treated with the company's products and the launch of Orenitram (treprostinil) extended-release tablets.The biotechnology company said net loss was $25.2 million, or $0.53 per diluted share, compared to a net income of $62.7 million, or $1.17 per diluted share, a year earlier. On a non-GAAP basis, however, it had net income of $207.9 million, or $3.91 per diluted share, which is well ahead of the mean estimate of $1.73 compiled by Capital IQ, if comparable. Meanwhile, revenues were $329.95 million, a huge improvement from last year's $302.23 million. The market's call was for $334.13 million, according to Capital IQ. United Therapeutics Corporation (NASDAQ:UTHR) is trading near the top of 52-week range $81.60 - $136.93.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
